Dietary Supplements Longevity June 2026
Vitamin K2 directs calcium into bones and away from arteries. Here’s what the Rotterdam Study and newer trials show — and how to supplement wisely.
Most people learn about vitamin K in the context of blood clotting and move on. That’s a shame, because the more interesting story about vitamin K is happening somewhere else entirely — in your arteries and your bones, where a specific form of the vitamin is quietly determining whether the calcium you absorb ends up strengthening your skeleton or hardening your blood vessels.
That form is vitamin K2. It’s distinct from the vitamin K1 you get from leafy greens, it does a completely different job in the body, and most people in the Western world don’t get nearly enough of it. If you care about preventing age-related diseases, this is a gap worth closing. And if you’ve been taking calcium or vitamin D supplements without considering K2, there’s a reasonable argument that you’ve been giving your body only part of the picture.
K1 vs. K2: why the distinction matters
Both K1 and K2 are fat-soluble vitamins, both are involved in activating proteins that depend on vitamin K to function, and both have a role in blood clotting. The similarities largely end there.
Vitamin K1 (phylloquinone) is abundant in green vegetables and is rapidly cleared from the bloodstream after use. Its primary job is activating clotting factors in the liver. Vitamin K2 (menaquinone) has a longer side chain, stays in circulation far longer, and reaches tissues beyond the liver — most importantly, the bones, the arterial walls, and the kidneys. Where K1 handles clotting, K2 handles calcium.
The landmark Rotterdam Study, which tracked 4,807 adults for roughly a decade and was published in the Journal of Nutrition in 2004, made this distinction concrete. Higher dietary K2 intake correlated with a 57% lower risk of coronary heart disease (CHD) mortality and a 52% lower risk of severe aortic calcification in the highest tertile compared to the lowest. K1 intake showed no protective effect on either outcome. That’s not a subtle difference in degree — it’s a complete divergence in function.
What K2 actually does: the calcium paradox explained
Here is the core problem K2 solves. Calcium is essential for strong bones, but excess calcium in the wrong places — specifically, in arterial walls — is one of the primary drivers of cardiovascular aging. Coronary artery calcification (CAC) is an early marker of atherosclerosis, and a strong independent predictor of heart attacks, heart failure, and stroke.
The body uses two vitamin K-dependent proteins to manage this:
Matrix Gla protein (MGP): An inhibitor of vascular calcification. MGP requires K2-dependent carboxylation (activation) to work. When K2 is insufficient, MGP stays uncarboxylated and inactive — and calcium deposits accumulate in arterial walls unchecked.
Osteocalcin: A protein that binds calcium in bone. It also requires K2-dependent carboxylation to function. Without adequate K2, osteocalcin remains undercarboxylated, and calcium that should be mineralizing bone stays free in circulation.
The result of chronic K2 deficiency is, in effect, the calcium paradox: bones become weaker while arteries become harder. This is not a coincidence — it’s a direct consequence of the same protein activation failure happening in two different tissues simultaneously. K2 is what coordinates calcium traffic, and without it, the routing goes wrong. Understanding how cell health breaks down at this level explains why K2 is increasingly on the radar of longevity researchers.
What the research shows
Cardiovascular protection
The Rotterdam Study was the starting point, but it’s far from the only data. A subsequent Dutch study published in Nutrition, Metabolism and Cardiovascular Diseases in 2009 extended the finding, showing that higher menaquinone intake was associated with reduced incidence of CHD — again with no corresponding benefit from K1.
The most compelling recent clinical evidence comes from the VitaK-CAC Trial — a double-blind, randomized, placebo-controlled trial in 180 patients with existing coronary artery disease and baseline CAC scores between 50 and 400 Agatston units. Initial results, presented at the European Society of Hypertension meeting in Milan in May 2025, showed that two years of daily supplementation with 360 mcg of menaquinone-7 (MK-7) slowed the progression of CAC compared to placebo, independent of blood pressure status. This was a trial in people who already had significant coronary artery disease — which makes the result more conservative than typical prevention studies, and arguably more meaningful.
A 2025 post-hoc analysis of a separate one-year MK-7 trial found that supplementation significantly reduced vascular stiffness and improved blood pressure in postmenopausal women with low K2 status — the first confirmation of a blood pressure benefit from K2 supplementation.
That said, the K2-cardiovascular picture isn’t entirely settled. Some larger observational analyses have found weaker associations, and a few pooled analyses have not found statistically significant effects on arterial stiffness or cardiovascular mortality. The balance of evidence is positive, particularly for calcification as an endpoint, but this is an area where the science is still accumulating. If your heart health is a primary concern, K2 should be part of the conversation with your doctor — not a replacement for it.
Bone health
K2 has a longer track record in bone research, particularly in Japan, where the MK-4 form has been approved as a prescription treatment for osteoporosis for decades.
A 2022 meta-analysis of 16 randomized controlled trials (RCTs) covering 6,425 participants in postmenopausal women found that vitamin K2 supplementation produced a statistically significant improvement in lumbar spine bone mineral density (BMD) and was associated with reduced fracture incidence. A 2024 systematic review and meta-analysis of RCTs in middle-aged and older adults concluded that K2 specifically maintains or increases lumbar spine BMD and favorably shifts the ratio of carboxylated to undercarboxylated osteocalcin — the functional marker of bone calcium utilization. A further 2025 meta-analysis in Frontiers in Endocrinology confirmed that K2 supplementation improves bone turnover markers in postmenopausal women with osteoporosis.
The bone fracture data is meaningful, but deserves a caveat: the evidence is stronger for vertebral fractures than for hip fractures, and the effect on femoral BMD has not been statistically significant in all meta-analyses. K2 is not a substitute for the interventions with the most robust fracture-prevention evidence — weight-bearing exercise, adequate calcium and vitamin D, and where indicated, prescription bone medications. For more context on bone health and what actually moves the needle on fracture risk, that article covers the bigger picture.
The D3-K2 pairing
Vitamin D3 increases intestinal calcium absorption — which is why so many people take it. The problem is that absorbing more calcium doesn’t automatically mean it ends up in bone. That depends on whether K2 is present to activate the proteins that direct it there.
This creates a practical concern: high-dose vitamin D3 supplementation without adequate K2 may increase the amount of free calcium in circulation without ensuring it reaches bone — leaving more of it available to deposit in arterial walls. The relationship between D3 and K2 is not fully established in clinical trials, but the mechanistic logic is sound, and many longevity-focused clinicians recommend pairing them. If you’re already supplementing with D3, adding K2 is a low-risk, low-cost complement worth considering. Keep.Health covers vitamin D supplementation in the anti-aging dietary supplements article.
Forms of K2: MK-4 vs. MK-7
Vitamin K2 comes in several menaquinone subtypes, but two dominate the supplement market: MK-4 and MK-7.
| MK-4 | MK-7 | |
|---|---|---|
| Source | Animal foods (butter, eggs, meat) | Fermented foods (especially natto) |
| Half-life | ~6–8 hours | ~68 hours |
| Typical dose | 45 mg/day, split into 3 doses | 90–200 mcg/day, once daily |
| Research basis | Japanese osteoporosis trials | Dutch/European cardiovascular trials |
| Bone evidence | Strong (Japanese studies) | Good (multiple RCTs) |
| Cardiovascular evidence | Limited | Strongest (Rotterdam, VitaK-CAC) |
The short half-life of MK-4 is the key practical difference. Because MK-4 clears the bloodstream in 6 to 8 hours, therapeutic doses in clinical trials have run as high as 45 mg/day divided into three doses — a dose that would be virtually impossible to reach from food and that is far higher than anything found in most Western supplements. MK-7, derived mainly from fermented soybeans (natto), has a half-life of roughly 68 hours, which allows it to accumulate in the body and be taken once daily in microgram-level doses.
For most people outside Japan looking to supplement for cardiovascular and general longevity purposes, MK-7 is the more practical and better-studied choice. The cardiovascular trials — including VitaK-CAC and the arterial stiffness studies — have used MK-7. Look for supplements labeled as “all-trans MK-7,” which is the biologically active isomer, with at least 97–99% trans configuration confirmed.
How much to take and what to look for
Most MK-7 supplements are sold in the 90–200 mcg range. The cardiovascular trials cited above used 360 mcg/day (VitaK-CAC) and 180 mcg/day (the arterial stiffness trial). The bone studies have generally used 90–180 mcg/day. For most adults, 100–200 mcg of all-trans MK-7 daily is the dose range supported by the bulk of clinical evidence.
There is no established tolerable upper intake level (UL) for vitamin K2 from the NIH Office of Dietary Supplements, and no documented cases of toxicity from dietary or supplemental K2 in otherwise healthy people. Vitamin K does not accumulate to harmful levels the way fat-soluble vitamins A and D can.
K2 is fat-soluble, so take it with a meal that contains some fat for optimal absorption.
A critical drug interaction to know: Vitamin K2 has a serious interaction with warfarin (Coumadin) and other vitamin K antagonist anticoagulants, which work precisely by blocking vitamin K activity. If you take warfarin or any anticoagulant, do not add K2 supplementation without discussing it with your prescribing physician. The same applies to bile acid sequestrants (cholestyramine, colestipol) and the weight-loss drug orlistat, which can reduce K absorption.
For independent quality verification of specific brands, ConsumerLab is the most reliable resource. Research cited in the supplement industry has noted that a meaningful proportion of tested K2 products fail to meet label claims — which makes third-party certification worth checking.
Food sources
Western diets are notably low in K2, which is part of why deficiency is so widespread. The richest dietary sources are:
- Natto (fermented soybeans): by far the highest source of MK-7, with a small serving providing several hundred micrograms. Common in Japan; an acquired taste for most Western palates
- Hard cheeses (Gouda, Edam, Brie): moderate MK-4 and longer-chain menaquinones from fermentation
- Soft cheeses: some K2, lower than hard cheeses
- Egg yolks: MK-4, amount depends heavily on whether the hens were pasture-raised
- Butter and cream from grass-fed animals: MK-4 in modest amounts
- Chicken liver and other organ meats: meaningful MK-4 content
K1, which is abundant in spinach, kale, broccoli, and other greens, does not substitute for K2’s functions in the arterial wall and bone — a point the Rotterdam Study made clearly. Eating leafy greens is excellent for many reasons, but it won’t address K2 deficiency. For more on building a diet that supports longevity across multiple dimensions, see Don’t Die from Diet.
Who should pay closest attention
K2 is worth considering for virtually anyone in the 40-plus age range. It’s particularly relevant for:
- People with known coronary artery calcification or elevated cardiovascular risk
- Postmenopausal women, for whom bone loss accelerates rapidly
- People taking calcium or vitamin D3 supplements without K2
- Anyone whose diet is low in fermented foods, hard cheeses, and pasture-raised animal products
- People with osteopenia or osteoporosis who want to support the effect of prescription bone medications
K2 supplementation is not appropriate without medical supervision for people taking warfarin or other vitamin K antagonists.
If you’ve already set up a health baseline with regular blood work, note that standard panels don’t measure K2 status directly. The most meaningful biomarker is dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP) — a marker of functional K2 deficiency used in research settings — but this isn’t yet part of routine clinical testing. In the meantime, dietary history and cardiovascular risk markers like CAC scoring give the most actionable picture. Our guide to measuring your biological health covers which tests are worth tracking.
The honest bottom line
Vitamin K2 has a plausible mechanism, a solid epidemiological foundation in the Rotterdam Study, and a growing body of clinical trial data pointing toward real cardiovascular and bone benefits. The VitaK-CAC Trial result — showing slowed CAC progression in patients with existing coronary artery disease — is particularly notable because it used a hard imaging endpoint in a sick population, not just biomarkers in healthy volunteers.
The evidence isn’t as extensive as it is for some better-studied supplements. Individual trials have sometimes produced mixed results, pooled analyses don’t all agree, and the optimal dose and form aren’t definitively established. K2 is not a replacement for the lifestyle and medical interventions with the most robust evidence for cardiovascular and bone health.
What it is: a low-cost, low-risk supplement with a compelling mechanistic rationale, meaningful observational evidence, and a growing clinical trial record — particularly for the MK-7 form. A quality MK-7 supplement typically runs $15–25 for a two- to three-month supply, which is not a significant barrier. For most people over 40 who don’t eat natto regularly, adding 100–200 mcg of all-trans MK-7 daily with a fat-containing meal is a reasonable and well-supported choice.
Consult your personal health team before starting, especially if you take any medications, have a clotting disorder, or are managing an active cardiovascular condition.
Frequently asked questions
What is vitamin K2, and how is it different from K1?
Vitamin K2 (menaquinone) is a fat-soluble vitamin that activates proteins responsible for directing calcium into bones and preventing it from depositing in arterial walls. Vitamin K1 (phylloquinone), found in leafy green vegetables, primarily supports blood clotting in the liver. The two forms perform different jobs in different tissues — which is why K1 intake showed no cardiovascular or bone benefit in the Rotterdam Study while K2 intake did.
What is the best form of K2 to supplement with?
For most adults, all-trans MK-7 at 100–200 mcg/day is the most practical and well-researched choice. It has a half-life of roughly 68 hours (versus 6–8 hours for MK-4), allows once-daily dosing, and is the form used in the cardiovascular trials with the strongest results. Look for the “all-trans” designation and third-party quality verification from ConsumerLab.
Can I take K2 with vitamin D3?
Yes, and there’s a good mechanistic argument for pairing them. Vitamin D3 increases calcium absorption; K2 activates the proteins that direct absorbed calcium into bone and away from arteries. Taking D3 without K2 may increase circulating calcium without ensuring it reaches bone. The combination is widely used among longevity-focused clinicians, though large randomized controlled trials specifically testing D3+K2 together are still limited.
Is vitamin K2 safe? Are there side effects?
Vitamin K2 has no established upper intake level and no documented toxicity in otherwise healthy people. The major safety concern is a serious interaction with warfarin and other vitamin K antagonist anticoagulants — if you take these medications, do not supplement with K2 without your doctor’s guidance. Bile acid sequestrants and orlistat may also reduce K absorption and should be discussed with your prescribing physician.
